Skip to main content
BrainCited

Acetyl-L-Carnitine لـ Age-Related Cognitive Decline

C الأدلة أدلة محدودة من دراسات صغيرة، غير أن ثمة بعض الإشارات الإيجابية.

Mixed results in healthy adults but more consistently positive outcomes in elderly populations with existing cognitive concerns. Used as a prescription drug in some European countries for cognitive impairment.

<\/script>\n
`; }, get iframeSnippet() { const domain = 'braincited.com'; const params = 'ingredient\u003Dacetyl\u002Dl\u002Dcarnitine\u0026condition\u003Dcognitive\u002Ddecline'; return ``; }, get activeSnippet() { return this.method === 'script' ? this.scriptSnippet : this.iframeSnippet; }, copySnippet() { navigator.clipboard.writeText(this.activeSnippet).then(() => { this.copied = true; setTimeout(() => { this.copied = false; }, 2000); }); } }" @keydown.escape.window="open = false" @click.outside="open = false">

Embed This Widget

Style



      
      
    

Widget powered by . Free, no account required.

C

الخلاصة

Mixed results in healthy adults but more consistently positive outcomes in elderly populations with existing cognitive concerns. Used as a prescription drug in some European countries for cognitive impairment.

Key Study Findings

Randomized Controlled Trial
Comparative study of choline alfoscerate as a combination therapy with donepezil: A mixed double-blind randomized …
Dose: None مقابل: None Outcome: Cognitive decline التأثير: None None

المجتمع المدروس: Alzheimer's disease patients

Systematic Review
Acetyl-L-Carnitine in Dementia and Other Cognitive Disorders: A Critical Update.
Dose: None مقابل: None Outcome: None التأثير: None None

المجتمع المدروس: None

Review
Chronic pain and adult hippocampal neurogenesis: translational implications from preclinical studies.
Dose: None مقابل: None Outcome: None التأثير: None None

المجتمع المدروس: Chronic pain patients (preclinical review)

Review
Alpha-synuclein, epigenetics, mitochondria, metabolism, calcium traffic, & circadian dysfunction in Parkinson's disease. An integrated strategy …
Dose: None مقابل: None Outcome: None التأثير: None None

المجتمع المدروس: Parkinson's disease patients

Controlled Clinical Trial
Effect of mitochondrial cofactors and antioxidants supplementation on cognition in the aged canine.
Dose: mitochondrial cofactors + antioxidants مقابل: control diet Outcome: cognitive function in aged dogs التأثير: improved learning and memory None

المجتمع المدروس: Aged beagle dogs

Randomized Controlled Trial n=106 Double-blind
A Phase II Randomized Clinical Trial of a Nutritional Formulation for Cognition and Mood in …
Dose: None مقابل: placebo Outcome: None التأثير: None p = 0.0083

المجتمع المدروس: Alzheimer's disease patients

Key Statistics

14

الدراسات

1000

المشاركون

Positive

C

التقييم

Referenced Papers

The Cochrane database … 2015 33 اقتباسات
The Cochrane database … 2003 94 اقتباسات
Alternative medicine review … 1999 112 اقتباسات
La Clinica terapeutica 1990 3 اقتباسات

Dosage & Usage

mg = milligrams · mcg = micrograms (1,000× smaller) · IU = International Units

الجرعات الشائعة

general:
500-2,000 mg/day
cognitivesupport:
1,500-3,000 mg/day

الحد الأعلى: Well-tolerated up to 3,000 mg/day

الجرعات المدروسة في الأبحاث

الجرعة المدة التأثير ن
None -- Positive --
None -- Positive --
None -- Mixed --
None -- Mixed --
mitochondrial cofactors + antioxidants -- Positive --
None -- Positive 106
None -- Positive 427
None 8.0 weeks Positive --

أفضل وقت للتناول: Morning, on empty stomach or with meals

Safety & Side Effects

الآثار الجانبية المُبلّغ عنها

  • Gastrointestinal discomfort (nausea, vomiting, diarrhea)
  • Fishy body odor
  • Restlessness or insomnia
  • Increased appetite

التفاعلات المعروفة

  • Anticoagulants (may increase bleeding risk)
  • Thyroid medications (may enhance thyroid hormone effects)
  • AZT (antiretroviral — may reduce neuropathy)

الحد الأقصى المسموح به: Well-tolerated up to 3,000 mg/day

استشر مقدم الرعاية الصحية دائماً قبل البدء بأي مكمل غذائي.

Frequently Asked Questions

Does Acetyl-L-Carnitine help with Age-Related Cognitive Decline?
Based on 14 studies with 1,000 participants, there is limited but promising evidence that Acetyl-L-Carnitine may support Age-Related Cognitive Decline management. Our evidence grade is C (Some Evidence).
How much Acetyl-L-Carnitine should I take for Age-Related Cognitive Decline?
Studies have used various dosages. A commonly studied range is 500-2,000 mg/day. Always consult your healthcare provider before starting any supplement regimen.
Are there side effects of Acetyl-L-Carnitine?
Reported side effects may include Gastrointestinal discomfort (nausea, vomiting, diarrhea), Fishy body odor, Restlessness or insomnia, Increased appetite. Most side effects are mild and dose-dependent. Consult your doctor if you experience any adverse reactions.
How strong is the evidence for Acetyl-L-Carnitine and Age-Related Cognitive Decline?
We rate the evidence as Grade C (Some Evidence). This rating is based on 14 peer-reviewed studies with 1,000 total participants. The overall direction of effect is positive.

References

  1. [1] Wankiun Lee et al.. Medicine (Baltimore). 2024. Comparative study of choline alfoscerate as a combination therapy with donepezil: A mixed double-blind randomized controlled and open-label observation trial. doi:10.1097/MD.0000000000038067 PubMed
  2. [2] Manuela Pennisi et al.. Nutrients. 2020. Acetyl-L-Carnitine in Dementia and Other Cognitive Disorders: A Critical Update. doi:10.3390/nu12051389 PubMed
  3. [3] Oliver T Phillipson. Ageing Res Rev. 2017. Alpha-synuclein, epigenetics, mitochondria, metabolism, calcium traffic, & circadian dysfunction in Parkinson's disease. An integrated strategy for management. doi:10.1016/j.arr.2017.09.006 PubMed
  4. [4] Mariagrazia Grilli. J Pain Res. 2017. Chronic pain and adult hippocampal neurogenesis: translational implications from preclinical studies. doi:10.2147/JPR.S146399 PubMed
  5. [5] Shikha Snigdha et al.. Neurobiol Aging. 2016. Effect of mitochondrial cofactors and antioxidants supplementation on cognition in the aged canine. doi:10.1016/j.neurobiolaging.2015.09.015 PubMed
  6. [6] Ruth Remington et al.. J Alzheimers Dis. 2015. A Phase II Randomized Clinical Trial of a Nutritional Formulation for Cognition and Mood in Alzheimer's Disease. doi:10.3233/JAD-142499 PubMed
  7. [7] Nuala Livingstone et al.. Cochrane Database Syst Rev. 2015. Pharmacological interventions for cognitive decline in people with Down syndrome. doi:10.1002/14651858.CD011546.pub2 PubMed
  8. [8] Debora Cutuli et al.. Front Aging Neurosci. 2014. n-3 polyunsaturated fatty acids supplementation enhances hippocampal functionality in aged mice. doi:10.3389/fnagi.2014.00220 PubMed
  9. [9] A Chan et al.. J Nutr Health Aging. 2010. A vitamin/nutriceutical formulation improves memory and cognitive performance in community-dwelling adults without dementia. doi:10.1007/s12603-010-0054-5 PubMed
  10. [10] James Suchy et al.. Nutr Res. 2009. Dietary supplementation with a combination of alpha-lipoic acid, acetyl-L-carnitine, glycerophosphocoline, docosahexaenoic acid, and phosphatidylserine reduces oxidative damage to murine brain … doi:10.1016/j.nutres.2008.11.004 PubMed
  11. [11] Parris M Kidd. Altern Med Rev. 2008. Alzheimer's disease, amnestic mild cognitive impairment, and age-associated memory impairment: current understanding and progress toward integrative prevention. PubMed
  12. [12] N W Milgram et al.. FASEB J. 2007. Acetyl-L-carnitine and alpha-lipoic acid supplementation of aged beagle dogs improves learning in two landmark discrimination tests. doi:10.1096/fj.07-8531com PubMed
  13. [13] S Hudson et al.. Cochrane Database Syst Rev. 2003. Acetyl-L-carnitine for dementia. doi:10.1002/14651858.CD003158 PubMed
  14. [14] P M Kidd. Altern Med Rev. 1999. A review of nutrients and botanicals in the integrative management of cognitive dysfunction. PubMed
  15. [15] M Neri et al.. Clin Ter. 1990. [Methodology of a clinical controlled study of L-acetylcarnitine]. PubMed
  16. [16] W M Herrmann et al.. Int J Clin Pharmacol Res. 1990. Pharmaco-electroencephalographic and clinical effects of the cholinergic substance--acetyl-L-carnitine--in patients with organic brain syndrome. PubMed

إخلاء مسؤولية FDA: لم تُقيَّم هذه البيانات من قبل إدارة الغذاء والدواء (FDA). لا تهدف المنتجات والمعلومات الواردة في هذا الموقع إلى تشخيص أو علاج أو شفاء أو الوقاية من أي مرض. تستند تقييمات الأدلة المعروضة إلى تحليلنا للأبحاث المحكّمة المنشورة ولا تُشكّل نصيحة طبية. استشر مقدم الرعاية الصحية دائماً قبل البدء بأي نظام مكملات.